Skip to main content
Erschienen in: International Journal of Colorectal Disease 5/2022

06.04.2022 | Original Article

Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence—a systematic review and meta-analysis

verfasst von: Yikuan Chen, Shaobo Mo, Mengdi Wu, Yaqi Li, Xi Chen, Junjie Peng

Erschienen in: International Journal of Colorectal Disease | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. After resection, patients need extensive follow-up to detect asymptomatic recurrences as early as possible to obtain optimal treatment. This study evaluated the prognostic value of circulating tumor DNA (ctDNA) for CRC recurrence.

Methods

Two investigators independently conducted a systematic literature search of peer-reviewed studies that investigated the prognostic value of ctDNA in CRC. Fixed effects or random effects models were applied for all analyses based on the assessment of heterogeneity.

Results

A total of 189 studies were initially retrieved from all databases; ultimately, eight studies with 879 CRC patients were included in this analysis. The pooled median recurrence-free survival was 11.36 months for ctDNA-positive patients. Meta-analysis of hazard ratio (HR) suggested that postoperative ctDNA-positive patients were more likely to experience cancer recurrence than ctDNA-negative patients (pooled HR: 5.41; 95% confidence interval (CI): 2.37–8.45).

Conclusions

Successive monitoring of ctDNA status and follow-up with postoperative computed tomography (CT)/magnetic resonance imaging (MRI) are useful tools to detect early recurrence in postoperative ctDNA-positive patients.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33CrossRef Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33CrossRef
2.
Zurück zum Zitat Christofori G (2006) New signals from the invasive front. Nature 441:444–450CrossRef Christofori G (2006) New signals from the invasive front. Nature 441:444–450CrossRef
3.
Zurück zum Zitat Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145–164CrossRef Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145–164CrossRef
4.
Zurück zum Zitat Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T et al (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20898 patients on 18 randomized trials. J Clin Oncol 27:872–877CrossRef Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T et al (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20898 patients on 18 randomized trials. J Clin Oncol 27:872–877CrossRef
5.
Zurück zum Zitat Sveen A, Kopetz S, Lothe RA (2020) Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 17:11–32CrossRef Sveen A, Kopetz S, Lothe RA (2020) Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 17:11–32CrossRef
6.
Zurück zum Zitat Rockall TA, McDonald PJ (1999) Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis 14:73–77CrossRef Rockall TA, McDonald PJ (1999) Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis 14:73–77CrossRef
7.
Zurück zum Zitat Shinkins B, Nicholson BD, Primrose J, Perera R, James T, Pugh S, Mant D (2017) The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLoS One 12:e0171810 Shinkins B, Nicholson BD, Primrose J, Perera R, James T, Pugh S, Mant D (2017) The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLoS One 12:e0171810
8.
Zurück zum Zitat Su BB, Shi H, Wan J (2012) Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol 18:2121–2126CrossRef Su BB, Shi H, Wan J (2012) Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol 18:2121–2126CrossRef
9.
Zurück zum Zitat Young GP, Pedersen SK, Mansfield S, Murray DH, Baker RT, Rabbitt P, Byrne S, Bambacas L, Hollington P, Symonds EL (2016) A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Med 5:2763–2772CrossRef Young GP, Pedersen SK, Mansfield S, Murray DH, Baker RT, Rabbitt P, Byrne S, Bambacas L, Hollington P, Symonds EL (2016) A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Med 5:2763–2772CrossRef
10.
Zurück zum Zitat Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R (2016) DNA methylation based biomarkers in colorectal cancer: a systematic review. Biochim Biophys Acta 1866:106–120PubMed Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R (2016) DNA methylation based biomarkers in colorectal cancer: a systematic review. Biochim Biophys Acta 1866:106–120PubMed
11.
Zurück zum Zitat Rasmussen SL, Krarup HB, Sunesen KG, Pedersen IS, Madsen PH, Thorlacius-Ussing O (2016) Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. Colorectal Dis 18:549–561CrossRef Rasmussen SL, Krarup HB, Sunesen KG, Pedersen IS, Madsen PH, Thorlacius-Ussing O (2016) Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. Colorectal Dis 18:549–561CrossRef
12.
Zurück zum Zitat Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:346ra92 Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:346ra92
13.
Zurück zum Zitat Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR (2021) Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. CA Cancer J Clin 71:176–190CrossRef Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR (2021) Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. CA Cancer J Clin 71:176–190CrossRef
14.
Zurück zum Zitat Jin S, Zhu D, Shao F, Chen S, Guo Y, Li K et al (2021) Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc Natl Acad Sci USA 118 Jin S, Zhu D, Shao F, Chen S, Guo Y, Li K et al (2021) Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc Natl Acad Sci USA 118
15.
Zurück zum Zitat Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H et al (2019) Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol 5:1124–1131CrossRef Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H et al (2019) Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol 5:1124–1131CrossRef
16.
Zurück zum Zitat Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ et al (2018) Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 36:1631–1641CrossRef Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ et al (2018) Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 36:1631–1641CrossRef
17.
Zurück zum Zitat Murray DH, Symonds EL, Young GP, Byrne S, Rabbitt P, Roy A, Cornthwaite K, Karapetis CS, Pedersen SK (2018) Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. J Cancer Res Clin Oncol 144:1741–1750CrossRef Murray DH, Symonds EL, Young GP, Byrne S, Rabbitt P, Roy A, Cornthwaite K, Karapetis CS, Pedersen SK (2018) Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. J Cancer Res Clin Oncol 144:1741–1750CrossRef
18.
Zurück zum Zitat Cai G, Cai M, Feng Z, Liu R, Liang L, Zhou P et al (2021) A multilocus blood-based assay targeting circulating tumor DNA methylation enables early detection and early relapse prediction of colorectal cancer. Gastroenterology 161:2053-2056.e2CrossRef Cai G, Cai M, Feng Z, Liu R, Liang L, Zhou P et al (2021) A multilocus blood-based assay targeting circulating tumor DNA methylation enables early detection and early relapse prediction of colorectal cancer. Gastroenterology 161:2053-2056.e2CrossRef
19.
Zurück zum Zitat Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M et al (2019) Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol 5:1710–1717CrossRef Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M et al (2019) Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol 5:1710–1717CrossRef
20.
Zurück zum Zitat Wang Y, Li L, Cohen JD, Kinde I, Ptak J, Popoli M et al (2019) Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncol 5:1118–1123CrossRef Wang Y, Li L, Cohen JD, Kinde I, Ptak J, Popoli M et al (2019) Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncol 5:1118–1123CrossRef
21.
Zurück zum Zitat Wong R, Tie J, Lee M, Cohen J, Wang Y, Li L et al (2019) The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. Int J Cancer 145:540–547CrossRef Wong R, Tie J, Lee M, Cohen J, Wang Y, Li L et al (2019) The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. Int J Cancer 145:540–547CrossRef
22.
Zurück zum Zitat Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K et al (2019) Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut 68:663–671CrossRef Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K et al (2019) Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut 68:663–671CrossRef
23.
Zurück zum Zitat Schøler LV, Reinert T, Ørntoft MW, Kassentoft CG, Árnadóttir SS, Vang S et al (2017) Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res 23:5437–5445CrossRef Schøler LV, Reinert T, Ørntoft MW, Kassentoft CG, Árnadóttir SS, Vang S et al (2017) Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res 23:5437–5445CrossRef
24.
Zurück zum Zitat Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537–540CrossRef Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537–540CrossRef
25.
Zurück zum Zitat Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24 Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24
26.
Zurück zum Zitat Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361:2449–2460CrossRef Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361:2449–2460CrossRef
27.
Zurück zum Zitat Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558CrossRef Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558CrossRef
28.
Zurück zum Zitat Nguyen LH, Goel A, Chung DC (2020) Pathways of colorectal carcinogenesis. Gastroenterology 158:291–302CrossRef Nguyen LH, Goel A, Chung DC (2020) Pathways of colorectal carcinogenesis. Gastroenterology 158:291–302CrossRef
29.
Zurück zum Zitat McGrath S, Zhao X, Qin ZZ, Steele R, Benedetti A (2019) One-sample aggregate data meta-analysis of medians. Stat Med 38:969–984CrossRef McGrath S, Zhao X, Qin ZZ, Steele R, Benedetti A (2019) One-sample aggregate data meta-analysis of medians. Stat Med 38:969–984CrossRef
30.
Zurück zum Zitat Chao M Gibbs P (2009) Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. J Clin Oncol 27:e279–80; author reply e281 Chao M Gibbs P (2009) Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. J Clin Oncol 27:e279–80; author reply e281
31.
Zurück zum Zitat Shin SJ, Chun SM, Kim TI, Kim YJ, Choi HJ, Jang SJ, Kim J (2017) Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping. PLoS One 12:e0176340 Shin SJ, Chun SM, Kim TI, Kim YJ, Choi HJ, Jang SJ, Kim J (2017) Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping. PLoS One 12:e0176340
32.
Zurück zum Zitat Allemani C, Rachet B, Weir HK, Richardson LC, Lepage C, Faivre J et al (2013) Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open 3:e003055 Allemani C, Rachet B, Weir HK, Richardson LC, Lepage C, Faivre J et al (2013) Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open 3:e003055
33.
Zurück zum Zitat Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet 394:1467–1480CrossRef Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet 394:1467–1480CrossRef
34.
Zurück zum Zitat McPhail S, Johnson S, Greenberg D, Peake M, Rous B (2015) Stage at diagnosis and early mortality from cancer in England. Br J Cancer 112(Suppl 1):S108–S115CrossRef McPhail S, Johnson S, Greenberg D, Peake M, Rous B (2015) Stage at diagnosis and early mortality from cancer in England. Br J Cancer 112(Suppl 1):S108–S115CrossRef
35.
Zurück zum Zitat Young PE, Womeldorph CM, Johnson EK, Maykel JA, Brucher B, Stojadinovic A, Avital I, Nissan A, Steele SR (2014) Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. J Cancer 5:262–271CrossRef Young PE, Womeldorph CM, Johnson EK, Maykel JA, Brucher B, Stojadinovic A, Avital I, Nissan A, Steele SR (2014) Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. J Cancer 5:262–271CrossRef
36.
Zurück zum Zitat Mo S, Dai W, Xiang W, Li Y, Feng Y, Zhang L, Li Q, Cai G (2019) Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer. Carcinogenesis 40:861–870CrossRef Mo S, Dai W, Xiang W, Li Y, Feng Y, Zhang L, Li Q, Cai G (2019) Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer. Carcinogenesis 40:861–870CrossRef
37.
Zurück zum Zitat Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH, Laurent-Puig P (2002) Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100:542–548CrossRef Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH, Laurent-Puig P (2002) Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100:542–548CrossRef
38.
Zurück zum Zitat Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, Alexandersen K, Huang YS, Tzou WS, Lin SR (2004) Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 28:721–726PubMed Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, Alexandersen K, Huang YS, Tzou WS, Lin SR (2004) Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 28:721–726PubMed
39.
Zurück zum Zitat Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA (2014) Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14:336CrossRef Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA (2014) Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14:336CrossRef
40.
Zurück zum Zitat Field K, Lipton L (2007) Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 13:3806–3815CrossRef Field K, Lipton L (2007) Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 13:3806–3815CrossRef
41.
Zurück zum Zitat Bergheim J, Semaan A, Gevensleben H, Groening S, Knoblich A, Dietrich J, Weber J, Kalff JC, Bootz F, Kristiansen G, Dietrich D (2018) Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. Br J Cancer 118:1217–1228CrossRef Bergheim J, Semaan A, Gevensleben H, Groening S, Knoblich A, Dietrich J, Weber J, Kalff JC, Bootz F, Kristiansen G, Dietrich D (2018) Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. Br J Cancer 118:1217–1228CrossRef
42.
Zurück zum Zitat Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh QD (2021) Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. JAMA Oncol 7:458–460CrossRef Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh QD (2021) Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. JAMA Oncol 7:458–460CrossRef
43.
Zurück zum Zitat Morris EJA, Goldacre R, Spata E, Mafham M, Finan PJ, Shelton J et al (2021) Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. Lancet Gastroenterol Hepatol 6:199–208CrossRef Morris EJA, Goldacre R, Spata E, Mafham M, Finan PJ, Shelton J et al (2021) Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. Lancet Gastroenterol Hepatol 6:199–208CrossRef
44.
Zurück zum Zitat Thierry AR, Pastor B, Pisareva E, Ghiringhelli F, Bouché O, De La Fouchardière C et al (2021) Association of COVID-19 lockdown with the tumor burden in patients with newly diagnosed metastatic colorectal cancer. JAMA Netw Open 4:e2124483 Thierry AR, Pastor B, Pisareva E, Ghiringhelli F, Bouché O, De La Fouchardière C et al (2021) Association of COVID-19 lockdown with the tumor burden in patients with newly diagnosed metastatic colorectal cancer. JAMA Netw Open 4:e2124483
45.
Zurück zum Zitat Crigna AT, Samec M, Koklesova L, Liskova A, Giordano FA, Kubatka P, Golubnitschaja O (2020) Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope? Epma J 11:1–25CrossRef Crigna AT, Samec M, Koklesova L, Liskova A, Giordano FA, Kubatka P, Golubnitschaja O (2020) Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope? Epma J 11:1–25CrossRef
Metadaten
Titel
Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence—a systematic review and meta-analysis
verfasst von
Yikuan Chen
Shaobo Mo
Mengdi Wu
Yaqi Li
Xi Chen
Junjie Peng
Publikationsdatum
06.04.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 5/2022
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-022-04144-4

Weitere Artikel der Ausgabe 5/2022

International Journal of Colorectal Disease 5/2022 Zur Ausgabe

Ist die Spülung bei Bohrlochtrepanation verzichtbar?

19.06.2024 Subduralhämatom Nachrichten

Wird ein chronisches Subduralhämatom per Bohrlochtrepanation entfernt, scheint eine subdurale Ausspülung mehr Vor- als Nachteile zu haben. Das legen Ergebnisse einer finnischen Studie nahe.

Was eine zu kleine Klappe für die Langzeitprognose bedeutet

18.06.2024 Aortenklappenersatz Nachrichten

Stellt sich nach der Implantation eines biologischen Aortenklappenersatzes die Prothese als zu klein für den Patienten heraus, hat das offenbar nur geringe Auswirkungen auf Langzeitüberleben und Reoperationsrisiko; zumindest solange die effektive Öffnungsfläche über 0,65 cm2/m2 liegt.

Antibiotika nach Appendektomie: Ist kürzer besser?

18.06.2024 Appendizitis Nachrichten

Nach einer Appendektomie wegen komplizierter Appendizitis scheint eine maximal dreitägige Antibiotikabehandlung hinreichend vor Komplikationen wie intraabdominellen Abszessen und Wundinfektionen zu schützen.

TAVI bei kleinem Aortenklappenanulus: Es gibt noch ungeklärte Fragen

13.06.2024 TAVI Nachrichten

Zwischen selbstexpandierenden und ballonexpandierbaren TAVI-Klappen scheinen bezüglich der Klappenfunktion bei Aortenstenose und kleinem Aortenklappenanulus Unterschiede zu bestehen. Aber sind die überhaupt von klinischer Relevanz? Eine neue Studie liefert dazu Informationen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.